SE505391C2 - Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet - Google Patents

Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet

Info

Publication number
SE505391C2
SE505391C2 SE9501991A SE9501991A SE505391C2 SE 505391 C2 SE505391 C2 SE 505391C2 SE 9501991 A SE9501991 A SE 9501991A SE 9501991 A SE9501991 A SE 9501991A SE 505391 C2 SE505391 C2 SE 505391C2
Authority
SE
Sweden
Prior art keywords
cortisol
use according
dexamethasone
metabolic syndrome
agonist
Prior art date
Application number
SE9501991A
Other languages
English (en)
Swedish (sv)
Other versions
SE9501991L (sv
SE9501991D0 (sv
Inventor
Per Maarin
Original Assignee
Cortendo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Ab filed Critical Cortendo Ab
Priority to SE9501991A priority Critical patent/SE505391C2/sv
Publication of SE9501991D0 publication Critical patent/SE9501991D0/xx
Priority to RU97121292/14A priority patent/RU2171471C2/ru
Priority to BR9608683-1A priority patent/BR9608683A/pt
Priority to CA002222215A priority patent/CA2222215A1/en
Priority to AU59173/96A priority patent/AU716671B2/en
Priority to DK96916423T priority patent/DK0835138T3/da
Priority to EP96916423A priority patent/EP0835138B1/en
Priority to PCT/SE1996/000708 priority patent/WO1996038179A1/en
Priority to AT96916423T priority patent/ATE235258T1/de
Priority to JP8536000A priority patent/JPH11505850A/ja
Priority to PT96916423T priority patent/PT835138E/pt
Priority to DE69626982T priority patent/DE69626982T2/de
Priority to CN96194229A priority patent/CN1078479C/zh
Priority to ES96916423T priority patent/ES2189872T3/es
Priority to US08/952,638 priority patent/US6410339B1/en
Publication of SE9501991L publication Critical patent/SE9501991L/
Publication of SE505391C2 publication Critical patent/SE505391C2/sv
Priority to NO19975492A priority patent/NO319829B1/no
Priority to MXPA/A/1997/009234A priority patent/MXPA97009234A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Combined Controls Of Internal Combustion Engines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SE9501991A 1995-05-30 1995-05-30 Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet SE505391C2 (sv)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SE9501991A SE505391C2 (sv) 1995-05-30 1995-05-30 Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet
US08/952,638 US6410339B1 (en) 1995-05-30 1996-05-30 Preparation for diagnosis of the metabolic syndrome and diseases including the syndrome
AT96916423T ATE235258T1 (de) 1995-05-30 1996-05-30 Zubereitung zur diagnostik des stoffwechselsyndroms und der dieses syndrom zeigende krankheiten
PT96916423T PT835138E (pt) 1995-05-30 1996-05-30 Preparacao para diagonostico da sindroma metabolica e doencas que incluem a sindroma
CA002222215A CA2222215A1 (en) 1995-05-30 1996-05-30 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome
AU59173/96A AU716671B2 (en) 1995-05-30 1996-05-30 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome
DK96916423T DK0835138T3 (da) 1995-05-30 1996-05-30 Præparat til diagnosticering af metabolisk syndrom og sygdomme relateret til dette syndrom
EP96916423A EP0835138B1 (en) 1995-05-30 1996-05-30 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome
PCT/SE1996/000708 WO1996038179A1 (en) 1995-05-30 1996-05-30 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome
RU97121292/14A RU2171471C2 (ru) 1995-05-30 1996-05-30 Способ диагностики метаболического синдрома и заболеваний, включающих в себя данный синдром
JP8536000A JPH11505850A (ja) 1995-05-30 1996-05-30 代謝症候群および該症候群を含む病気の診断のための製剤
BR9608683-1A BR9608683A (pt) 1995-05-30 1996-05-30 Preparação para diagnóstico de síndrome metabólica e doenças incluindo a síndrome
DE69626982T DE69626982T2 (de) 1995-05-30 1996-05-30 Zubereitung zur diagnostik des stoffwechselsyndroms und der dieses syndrom zeigende krankheiten
CN96194229A CN1078479C (zh) 1995-05-30 1996-05-30 诊断代谢综合症和包括该综合症疾病的试剂
ES96916423T ES2189872T3 (es) 1995-05-30 1996-05-30 Sistema de diagnostico del sindrome metabolico y enfermedades que presentan el sindrome.
MXPA/A/1997/009234A MXPA97009234A (en) 1995-05-30 1997-11-28 Preparation for the diagnosis of the metabolic syndrome and diseases that include the sindr
NO19975492A NO319829B1 (no) 1995-05-30 1997-11-28 Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501991A SE505391C2 (sv) 1995-05-30 1995-05-30 Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet

Publications (3)

Publication Number Publication Date
SE9501991D0 SE9501991D0 (sv) 1995-05-30
SE9501991L SE9501991L (sv) 1996-12-01
SE505391C2 true SE505391C2 (sv) 1997-08-18

Family

ID=20398470

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9501991A SE505391C2 (sv) 1995-05-30 1995-05-30 Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet

Country Status (16)

Country Link
US (1) US6410339B1 (pt)
EP (1) EP0835138B1 (pt)
JP (1) JPH11505850A (pt)
CN (1) CN1078479C (pt)
AT (1) ATE235258T1 (pt)
AU (1) AU716671B2 (pt)
BR (1) BR9608683A (pt)
CA (1) CA2222215A1 (pt)
DE (1) DE69626982T2 (pt)
DK (1) DK0835138T3 (pt)
ES (1) ES2189872T3 (pt)
NO (1) NO319829B1 (pt)
PT (1) PT835138E (pt)
RU (1) RU2171471C2 (pt)
SE (1) SE505391C2 (pt)
WO (1) WO1996038179A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217505B2 (en) * 1998-02-26 2007-05-15 Cortendo Ab Method for determining whether condition is symptom of metabolic syndrome
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
US20090117660A1 (en) * 2005-04-30 2009-05-07 Oakville Hong Kong Co., Limited Devices and methods for sample collection and analysis
RU2520080C2 (ru) * 2006-10-06 2014-06-20 Нестек С.А. Композиции и мультипараметричекие способы анализа для измерения биологических медиаторов физиологического здоровья
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
RU2444298C1 (ru) * 2010-07-15 2012-03-10 Учреждение Российской академии медицинских наук Научный центр клинической и экспериментальной медицины Сибирского отделения РАМН (НЦКЭМ СО РАМН) Способ диагностики метаболического синдрома
CN105973881A (zh) * 2016-04-27 2016-09-28 樊福好 一种检测机体活度的溶液及检测方法

Also Published As

Publication number Publication date
DE69626982T2 (de) 2004-03-04
NO975492D0 (no) 1997-11-28
RU2171471C2 (ru) 2001-07-27
DE69626982D1 (de) 2003-04-30
EP0835138A1 (en) 1998-04-15
WO1996038179A1 (en) 1996-12-05
EP0835138B1 (en) 2003-03-26
AU716671B2 (en) 2000-03-02
ES2189872T3 (es) 2003-07-16
AU5917396A (en) 1996-12-18
CN1078479C (zh) 2002-01-30
NO319829B1 (no) 2005-09-19
ATE235258T1 (de) 2003-04-15
CA2222215A1 (en) 1996-12-05
CN1185743A (zh) 1998-06-24
PT835138E (pt) 2003-08-29
JPH11505850A (ja) 1999-05-25
NO975492L (no) 1998-01-27
MX9709234A (es) 1998-10-31
US6410339B1 (en) 2002-06-25
SE9501991L (sv) 1996-12-01
DK0835138T3 (da) 2003-07-21
BR9608683A (pt) 1999-12-07
SE9501991D0 (sv) 1995-05-30

Similar Documents

Publication Publication Date Title
SE505391C2 (sv) Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet
Linnemann et al. Interleukin 6 protects pancreatic β cells from apoptosis by stimulation of autophagy
Norbiato et al. Cortisol resistance in acquired immunodeficiency syndrome
Hägg et al. Value of basal plasma cortisol assays in the assessment of pituitary‐adrenal insufficiency
Bennett et al. Low levels of somatomedin C in patients with the fibromyalgia syndrome. A possible link between sleep and muscle pain
Heuser et al. Age-associated changes of pituitary-adrenocortical hormone regulation in humans: importance of gender
Weyer et al. Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration.
D'Ercole et al. Serum somatomedin-C in hypopituitarism and in other disorders of growth
Talal et al. Elevated salivary and synovial fluid β2-microglobulin in Sjogren's syndrome and rheumatoid arthritis
Cowen et al. 5-HT1A receptor sensitivity in major depression: a neuroendocrine study with buspirone
Gertow et al. Expression of fatty-acid-handling proteins in human adipose tissue in relation to obesity and insulin resistance
Voice et al. c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide
Reagan et al. Hippocampal-specific insulin resistance elicits behavioral despair and hippocampal dendritic atrophy
Wodarz et al. Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression
Fiasche et al. Growth hormone neurosecretory disfunction in major depressive illness
Séron et al. Distinct impaired regulation of SOCS3 and long and short isoforms of the leptin receptor in visceral and subcutaneous fat of lean and obese women
Rahman et al. The effect of thyroxine on small intestinal motility in the elderly
Wolthers Methodological aspects of short-term knemometry in the assessment of exogenous glucocorticosteroid-induced growth suppression in children
Donahoo et al. Plasma α–melanocyte-stimulating hormone: sex differences and correlations with obesity
US7217505B2 (en) Method for determining whether condition is symptom of metabolic syndrome
Tvarijonaviciute et al. Serum adiponectin concentration in dogs—absence of diurnal variation and lack of effect of feeding and methylprednisolone administration
Lee et al. Pulsatile secretion pattern of growth hormone in dogs with pituitary-dependent hyperadrenocorticism
Leake et al. Plasma N-POMC, ACTH and cortisol following hCRH administration in major depression and dysthymia
MXPA97009234A (en) Preparation for the diagnosis of the metabolic syndrome and diseases that include the sindr
JP4044842B2 (ja) 肥満を処置し得る薬剤のスクリーニング法

Legal Events

Date Code Title Description
NUG Patent has lapsed